Overview: HLA Abacavir Hypersensitivity TestIntroduction: The HLA Abacavir Hypersensitivity Test detects HLA-B5701 to assess abacavir hypersensitivity risk, preventing severe reactions. Aligned with 2023 DHHS guidelines, it uses PCR for high specificity, supporting drug sensitivity screening. This test is critical for guiding safe antiretroviral therapy, avoiding hypersensitivity reactions, and improving outcomes in pharmacogenomics for patients with HIV considering abacavir treatment.Other Names: HLA-B5701 Assay, Abacavir Sensitivity Test.FDA Status: Laboratory-developed test (LDT), meeting pharmacogenomics standards for diagnostic accuracy.Historical Milestone: HLA-B5701 testing began in the 2000s after abacavir hypersensitivity was linked to this allele. PCR-based assays improved screening accuracy.Purpose: Assesses HLA-B5701 for abacavir hypersensitivity risk, guides safe antiretroviral therapy, and prevents severe reactions in HIV patients.Test Parameters: 1. HLA-B57:01Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva at any time. Report history of HIV, drug allergies, or family history of hypersensitivity.Specimen: 2-5 mL whole blood (EDTA), 1-2 buccal swabs (sterile swab), or 1-2 mL saliva (sterile container). Transport in a biohazard bag within 24 hours.Sample Stability at Room Temperature: 24 hoursSample Stability at Refrigeration: 48 hoursSample Stability at Frozen: Not frozenMedical History: Document history of HIV, drug allergies, or family history of hypersensitivity reactions. Include current medications, especially antiretrovirals.Consent: Written consent required, detailing the tests purpose, hypersensitivity implications, and potential need for alternative antiretroviral therapy.Procedural Considerations: Uses PCR to detect HLA-B5701. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often before abacavir initiation.Factors Affecting Result Accuracy: Improper sample handling or contamination can affect results. Low DNA quality may impact typing accuracy.Clinical Significance: Positive HLA-B5701 indicates high abacavir hypersensitivity risk, prompting alternative antiretroviral selection. Negative results suggest safe abacavir use but require clinical monitoring.Specialist Consultation: Consult an infectious disease specialist or pharmacogenomicist for result interpretation and therapy planning.Additional Supporting Tests: HIV RNA, CD4 count, or skin patch testing to assess HIV status and drug sensitivity.Test Limitations: Limited to HLA-B5701; other hypersensitivity causes may exist. Clinical correlation is needed.References: DHHS HIV Guidelines, 2023; Clinical Pharmacogenetics, Mallal S, 2022.